Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 10/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.37 |
| ▸ | CETP | P11597 | 6/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5072379 | 0.86 | TACR1 (0.43) | TACR1MEN1ALDH1A1KMT2A | |
| SCHEMBL1587634 | 0.84 | SLC6A4 (0.40) | TACR1SLC6A2SLC6A4CETP | |
| SCHEMBL129898 | 0.79 | CETP (0.43) | CETPALDH1A1 | |
| SCHEMBL1587621 | 0.78 | CETP (0.36) | TACR1SLC6A2SLC6A4CETP | |
| SCHEMBL132751 | 0.77 | ALDH1A1 (0.40) | TACR1CETPMEN1ALDH1A1KMT2A | |
| SCHEMBL1587620 | 0.76 | MGLL (0.38) | TACR1SLC6A2SLC6A4CETP | |
| SCHEMBL5067467 | 0.69 | TACR1 (0.40) | TACR1SLC6A2SLC6A4CETP | |
| SCHEMBL130203 | 0.66 | CETP (0.45) | SLC6A4CETP | |
| SCHEMBL130516 | 0.66 | CETP (0.56) | CETP | |
| SCHEMBL132026 | 0.65 | CETP (0.45) | CETPMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979331-B1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-8076364-B2 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-12-13 | — | — | US | disclosed |
| US-20110092506-A1 | TRISUBSTITUTED AMINE COMPOUND | NAKAMURA YOSHINORI | 2011-04-21 | — | — | US | disclosed |
| US-7906517-B2 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-03-15 | — | — | US | disclosed |
| US-20090029994-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092506-A1 | TRISUBSTITUTED AMINE COMPOUND | CETP, MTTP, APOB | TACR1 3049/4885SLC6A2 1191/4885SLC6A4 1347/4885 |
| US-20090029994-A1 | Trisubstituted amine compound | CETP, MTTP, APOB | TACR1 3049/4885SLC6A2 1191/4885SLC6A4 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.